Endocyte, Inc. (NASDAQ:ECYT) VP Christopher P. Leamon sold 5,036 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $9.07, for a total transaction of $45,676.52. Following the completion of the sale, the vice president now owns 143,470 shares of the company’s stock, valued at $1,301,272.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Endocyte, Inc. (NASDAQ:ECYT) traded up $0.63 during midday trading on Monday, hitting $8.83. 7,629,080 shares of the company’s stock were exchanged, compared to its average volume of 1,963,384. The stock has a market capitalization of $541.70, a PE ratio of -6.95 and a beta of 1.02. Endocyte, Inc. has a fifty-two week low of $1.17 and a fifty-two week high of $9.32.
Endocyte (NASDAQ:ECYT) last posted its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.02). The company had revenue of $0.01 million during the quarter. Endocyte had a negative return on equity of 40.33% and a negative net margin of 78,662.86%. The company’s revenue was up .0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.26) earnings per share. analysts expect that Endocyte, Inc. will post -0.96 earnings per share for the current year.
Several brokerages have weighed in on ECYT. BidaskClub upgraded shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Saturday, March 3rd. Zacks Investment Research upgraded shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Friday, February 9th. Cowen upgraded shares of Endocyte from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 27th. ValuEngine upgraded shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Finally, Wells Fargo & Co began coverage on shares of Endocyte in a report on Friday. They issued an “outperform” rating for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $7.00.
COPYRIGHT VIOLATION WARNING: This story was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3257994/endocyte-inc-ecyt-vp-sells-45676-52-in-stock.html.
Endocyte Company Profile
Endocyte Inc (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.